(MET) MetLife - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US59156R1086
Stock:
Total Rating 18
Risk 55
Buy Signal -0.42
| Risk 5d forecast | |
|---|---|
| Volatility | 36.5% |
| Relative Tail Risk | 1.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -28.62 |
| Character TTM | |
|---|---|
| Beta | 0.976 |
| Beta Downside | 1.178 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.84% |
| CAGR/Max DD | 0.17 |
EPS (Earnings per Share)
Revenue
Description: MET MetLife
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it offers fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity and funded reinsurance solutions; credit insurance products; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 3.38b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.21 > 1.0 |
| NWC/Revenue: 80.91% < 20% (prev 185.6%; Δ -104.7% < -1%) |
| CFO/TA 0.02 > 3% & CFO 18.11b > Net Income 3.38b |
| Net Debt (-2.70b) to EBITDA (5.72b): -0.47 < 3 |
| Current Ratio: 4.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (665.0m) vs 12m ago -4.72% < -2% |
| Gross Margin: 25.57% > 18% (prev 0.27%; Δ 2530 % > 0.5%) |
| Asset Turnover: 10.73% > 50% (prev 10.35%; Δ 0.38% > 0%) |
| Interest Coverage Ratio: 4.39 > 6 (EBITDA TTM 5.72b / Interest Expense TTM 1.06b) |
Altman Z'' 0.82
| A: 0.08 (Total Current Assets 79.07b - Total Current Liabilities 17.47b) / Total Assets 741.67b |
| B: 0.06 (Retained Earnings 44.29b / Total Assets 741.67b) |
| C: 0.01 (EBIT TTM 4.66b / Avg Total Assets 709.57b) |
| D: 0.04 (Book Value of Equity 26.22b / Total Liabilities 716.25b) |
| Altman-Z'' Score: 0.82 = B |
Beneish M -2.47
| DSRI: 1.47 (Receivables 49.06b/30.77b, Revenue 76.13b/70.13b) |
| GMI: 1.07 (GM 25.57% / 27.36%) |
| AQI: 1.11 (AQ_t 0.89 / AQ_t-1 0.80) |
| SGI: 1.09 (Revenue 76.13b / 70.13b) |
| TATA: -0.02 (NI 3.38b - CFO 18.11b) / TA 741.67b) |
| Beneish M-Score: -2.47 (Cap -4..+1) = BBB |
What is the price of MET shares?
As of March 04, 2026, the stock is trading at USD 73.24 with a total of 4,054,209 shares traded.
Over the past week, the price has changed by -2.66%, over one month by -7.60%, over three months by -3.29% and over the past year by -12.00%.
Over the past week, the price has changed by -2.66%, over one month by -7.60%, over three months by -3.29% and over the past year by -12.00%.
Is MET a buy, sell or hold?
MetLife has received a consensus analysts rating of 4.19.
Therefore, it is recommended to buy MET.
- StrongBuy: 7
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MET price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.7 | 25.2% |
| Analysts Target Price | 91.7 | 25.2% |
MET Fundamental Data Overview February 27, 2026
P/E Trailing = 15.5599
P/E Forward = 8.2305
P/S = 0.6438
P/B = 1.9536
P/EG = 0.8487
Revenue TTM = 76.13b USD
EBIT TTM = 4.66b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 18.62b USD (from longTermDebt, last quarter)
Short Term Debt = 355.0m USD (from shortTermDebt, last quarter)
Debt = 19.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.70b USD (from netDebt column, last quarter)
Enterprise Value = 46.92b USD (49.62b + Debt 19.33b - CCE 22.03b)
Interest Coverage Ratio = 4.39 (Ebit TTM 4.66b / Interest Expense TTM 1.06b)
EV/FCF = 2.59x (Enterprise Value 46.92b / FCF TTM 18.11b)
FCF Yield = 38.59% (FCF TTM 18.11b / Enterprise Value 46.92b)
FCF Margin = 23.78% (FCF TTM 18.11b / Revenue TTM 76.13b)
Net Margin = 4.44% (Net Income TTM 3.38b / Revenue TTM 76.13b)
Gross Margin = 25.57% ((Revenue TTM 76.13b - Cost of Revenue TTM 56.67b) / Revenue TTM)
Gross Margin QoQ = 30.53% (prev 17.40%)
Tobins Q-Ratio = 0.06 (Enterprise Value 46.92b / Total Assets 741.67b)
Interest Expense / Debt = 1.36% (Interest Expense 263.0m / Debt 19.33b)
Taxrate = 26.95% (301.0m / 1.12b)
NOPAT = 3.40b (EBIT 4.66b * (1 - 26.95%))
Current Ratio = 4.53 (Total Current Assets 79.07b / Total Current Liabilities 17.47b)
Debt / Equity = 0.68 (Debt 19.33b / totalStockholderEquity, last quarter 28.40b)
Debt / EBITDA = -0.47 (Net Debt -2.70b / EBITDA 5.72b)
Debt / FCF = -0.15 (Net Debt -2.70b / FCF TTM 18.11b)
Total Stockholder Equity = 28.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.48% (Net Income 3.38b / Total Assets 741.67b)
RoE = 12.01% (Net Income TTM 3.38b / Total Stockholder Equity 28.13b)
RoCE = 9.97% (EBIT 4.66b / Capital Employed (Equity 28.13b + L.T.Debt 18.62b))
RoIC = 7.14% (NOPAT 3.40b / Invested Capital 47.70b)
WACC = 7.12% (E(49.62b)/V(68.95b) * Re(9.51%) + D(19.33b)/V(68.95b) * Rd(1.36%) * (1-Tc(0.27)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.55%
[DCF] Terminal Value 82.28% ; FCFF base≈16.91b ; Y1≈18.12b ; Y5≈22.03b
[DCF] Fair Price = 710.0 (EV 462.54b - Net Debt -2.70b = Equity 465.24b / Shares 655.3m; r=7.12% [WACC]; 5y FCF grow 8.03% → 2.90% )
EPS Correlation: 53.87 | EPS CAGR: 4.91% | SUE: 1.01 | # QB: 1
Revenue Correlation: 40.86 | Revenue CAGR: 11.64% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.006 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=9.82 | Chg7d=+0.005 | Chg30d=-0.059 | Revisions Net=-4 | Growth EPS=+11.2% | Growth Revenue=+0.2%
EPS next Year (2027-12-31): EPS=10.99 | Chg7d=-0.004 | Chg30d=-0.052 | Revisions Net=+1 | Growth EPS=+11.9% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.1% (Discount Rate 9.5% - Earnings Yield 6.4%)
[Growth] Growth Spread = +6.7% (Analyst 9.8% - Implied 3.1%)
P/E Forward = 8.2305
P/S = 0.6438
P/B = 1.9536
P/EG = 0.8487
Revenue TTM = 76.13b USD
EBIT TTM = 4.66b USD
EBITDA TTM = 5.72b USD
Long Term Debt = 18.62b USD (from longTermDebt, last quarter)
Short Term Debt = 355.0m USD (from shortTermDebt, last quarter)
Debt = 19.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.70b USD (from netDebt column, last quarter)
Enterprise Value = 46.92b USD (49.62b + Debt 19.33b - CCE 22.03b)
Interest Coverage Ratio = 4.39 (Ebit TTM 4.66b / Interest Expense TTM 1.06b)
EV/FCF = 2.59x (Enterprise Value 46.92b / FCF TTM 18.11b)
FCF Yield = 38.59% (FCF TTM 18.11b / Enterprise Value 46.92b)
FCF Margin = 23.78% (FCF TTM 18.11b / Revenue TTM 76.13b)
Net Margin = 4.44% (Net Income TTM 3.38b / Revenue TTM 76.13b)
Gross Margin = 25.57% ((Revenue TTM 76.13b - Cost of Revenue TTM 56.67b) / Revenue TTM)
Gross Margin QoQ = 30.53% (prev 17.40%)
Tobins Q-Ratio = 0.06 (Enterprise Value 46.92b / Total Assets 741.67b)
Interest Expense / Debt = 1.36% (Interest Expense 263.0m / Debt 19.33b)
Taxrate = 26.95% (301.0m / 1.12b)
NOPAT = 3.40b (EBIT 4.66b * (1 - 26.95%))
Current Ratio = 4.53 (Total Current Assets 79.07b / Total Current Liabilities 17.47b)
Debt / Equity = 0.68 (Debt 19.33b / totalStockholderEquity, last quarter 28.40b)
Debt / EBITDA = -0.47 (Net Debt -2.70b / EBITDA 5.72b)
Debt / FCF = -0.15 (Net Debt -2.70b / FCF TTM 18.11b)
Total Stockholder Equity = 28.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.48% (Net Income 3.38b / Total Assets 741.67b)
RoE = 12.01% (Net Income TTM 3.38b / Total Stockholder Equity 28.13b)
RoCE = 9.97% (EBIT 4.66b / Capital Employed (Equity 28.13b + L.T.Debt 18.62b))
RoIC = 7.14% (NOPAT 3.40b / Invested Capital 47.70b)
WACC = 7.12% (E(49.62b)/V(68.95b) * Re(9.51%) + D(19.33b)/V(68.95b) * Rd(1.36%) * (1-Tc(0.27)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.55%
[DCF] Terminal Value 82.28% ; FCFF base≈16.91b ; Y1≈18.12b ; Y5≈22.03b
[DCF] Fair Price = 710.0 (EV 462.54b - Net Debt -2.70b = Equity 465.24b / Shares 655.3m; r=7.12% [WACC]; 5y FCF grow 8.03% → 2.90% )
EPS Correlation: 53.87 | EPS CAGR: 4.91% | SUE: 1.01 | # QB: 1
Revenue Correlation: 40.86 | Revenue CAGR: 11.64% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.49 | Chg7d=-0.006 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=9.82 | Chg7d=+0.005 | Chg30d=-0.059 | Revisions Net=-4 | Growth EPS=+11.2% | Growth Revenue=+0.2%
EPS next Year (2027-12-31): EPS=10.99 | Chg7d=-0.004 | Chg30d=-0.052 | Revisions Net=+1 | Growth EPS=+11.9% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.1% (Discount Rate 9.5% - Earnings Yield 6.4%)
[Growth] Growth Spread = +6.7% (Analyst 9.8% - Implied 3.1%)